6-benzoyl-3-(trifluoromethyl)-2(1H)-quinoxalinone | 143309-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-benzoyl-3-(trifluoromethyl)-2(1H)-quinoxalinone
• 英文别名: 6-benzoyl-3-trifluoromethylquinoxalin-2(1H)-one；6-benzoyl-3-(trifluoromethyl)-1H-quinoxalin-2-one
• CAS: 143309-79-9
• 化学式: C₁₆H₉F₃N₂O₂
• 分子量: 318.255
• InChiKey: JLSQMAHPQIPVSN-UHFFFAOYSA-N

物化性质

• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-benzoyl-3-(trifluoromethyl)-2(1H)-quinoxalinone 在 三溴化磷 作用下， 反应 5.0h， 以73%的产率得到(2-bromo-3-trifluoromethyl-quinoxalin-6-yl)phenyl methanone
  参考文献：
  名称：

  Non-peptide GLP-1 agonists

  摘要：

  新型非肽类GLP-1激动剂，包括它们的药物组合物，使用非肽类GLP-1激动剂制备药物组合物以及治疗和/或预防激活人类GLP-1受体有益的疾病和疾病的方法，特别是代谢性疾病，如IGT、1型糖尿病、2型糖尿病和肥胖症。

  公开号：

  US06927214B1
• 作为产物：
  描述：

  六氟环氧丙烷 、 3,4-二氨基二苯甲酮 在 碳酸氢钠 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以13%的产率得到7-benzoyl-3-(trifluoromethyl)-2(1H)-quinoxalinone
  参考文献：
  名称：

  Fluorine-19 NMR studies on the mechanism of riboflavin synthase. Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine

  摘要：

  The reactions of hexafluoropropene oxide (19), methyl trifluoropyruvate (21), and 1,1,1-trifluorobutane-2,3-dione (45) with a series of ortho diamines were investigated as an approach to the synthesis of trifluoromethyl-substituted quinoxalinones and lumazines. 6-(Trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine (11) was synthesized by reaction of methyl trifluoropyruvate (21) with 5-amino-6-(D-ribitylamino)-2,4(1H,3H)-pyrimidinedione (3) hydrochloride and utilized as a F-19 NMR probe of the light riboflavin synthase of Bacillus subtilis. The fluorolumazine 11 was found to be an inhibitor of the enzyme with an inhibition constant K(I) = 55 muM. Equilibrium dialysis experiments indicated the binding of six molecules of 11 per enzyme molecule, corresponding to one molecule bound at each of the three donor and three acceptor sites of the enzyme. The apparent dissociation constants K(D) were approximately 4 and 112 muM. The enzyme-bound ligand gave rise to several broad F-19 NMR signals which were shifted to low field. The bound ligand 11 could be displaced from the enzyme by the enzyme product, riboflavin (2), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione (56). 6-(Trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine (13) was synthesized by reaction of the hydrochloride salt of 3 with 1,1,1-trifluorobutane-2,3-dione (45). Three molecules of 13 can be bound relatively tightly per mole of riboflavin synthase, i.e., one ligand molecule per protein subunit. The inhibition constant K(I) was determined to be 75 muM, while dissociation constants of 17 and 70 muM were determined by equilibrium dialysis and F-19 NMR, respectively. The bound ligand 13 could also be displaced by riboflavin and product analog 56. A scheme for the catalytic cycle of riboflavin synthase is proposed.

  DOI：

  10.1021/jo00047a015

文献信息

• US6927214B1
  申请人：——

  公开号：US6927214B1

  公开（公告）日：2005-08-09
• Non-peptide GLP-1 agonists
  申请人：Teng Min

  公开号：US06927214B1

  公开（公告）日：2005-08-09

  Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.

  新型非肽类GLP-1激动剂，包括它们的药物组合物，使用非肽类GLP-1激动剂制备药物组合物以及治疗和/或预防激活人类GLP-1受体有益的疾病和疾病的方法，特别是代谢性疾病，如IGT、1型糖尿病、2型糖尿病和肥胖症。
• Fluorine-19 NMR studies on the mechanism of riboflavin synthase. Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine
  作者：Mark Cushman、Hemantkumar H. Patel、Johannes Scheuring、Adelbert Bacher

  DOI：10.1021/jo00047a015

  日期：1992.10

  The reactions of hexafluoropropene oxide (19), methyl trifluoropyruvate (21), and 1,1,1-trifluorobutane-2,3-dione (45) with a series of ortho diamines were investigated as an approach to the synthesis of trifluoromethyl-substituted quinoxalinones and lumazines. 6-(Trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine (11) was synthesized by reaction of methyl trifluoropyruvate (21) with 5-amino-6-(D-ribitylamino)-2,4(1H,3H)-pyrimidinedione (3) hydrochloride and utilized as a F-19 NMR probe of the light riboflavin synthase of Bacillus subtilis. The fluorolumazine 11 was found to be an inhibitor of the enzyme with an inhibition constant K(I) = 55 muM. Equilibrium dialysis experiments indicated the binding of six molecules of 11 per enzyme molecule, corresponding to one molecule bound at each of the three donor and three acceptor sites of the enzyme. The apparent dissociation constants K(D) were approximately 4 and 112 muM. The enzyme-bound ligand gave rise to several broad F-19 NMR signals which were shifted to low field. The bound ligand 11 could be displaced from the enzyme by the enzyme product, riboflavin (2), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione (56). 6-(Trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine (13) was synthesized by reaction of the hydrochloride salt of 3 with 1,1,1-trifluorobutane-2,3-dione (45). Three molecules of 13 can be bound relatively tightly per mole of riboflavin synthase, i.e., one ligand molecule per protein subunit. The inhibition constant K(I) was determined to be 75 muM, while dissociation constants of 17 and 70 muM were determined by equilibrium dialysis and F-19 NMR, respectively. The bound ligand 13 could also be displaced by riboflavin and product analog 56. A scheme for the catalytic cycle of riboflavin synthase is proposed.